Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-092040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-04 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | M - OptEx | — | +9,409 | 16.4K | +134% | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | F - Tax | $29.32 | -3,138 | 13.3K | -19% | -$92.0K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Beetham Thomas W. | COO | M - OptEx | $0.00 | -9,409 | 28.2K | -25% | $0 |
| DM | 2026-03-04 | 2026-03-02 | VRDN | Beetham Thomas W. | COO | A - Grant | $0.00 | +211.8K | 176.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-03 | M | A | 9,409 | — | 16,409 | D | — | — | (F2) Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. (F5) Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c). |
| 2 | Common | Common Stock | 2026-03-03 | F | D | 3,138 | $29.32 | 13,271 | D | — | — | (F5) Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c). |
| 3 | Derivative | Restricted Stock Units | 2026-03-03 | M | D | 9,409 | $0.00 | 28,227 | D | — · — to — | 9,409 Common Stock | (F2) Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. (F4) The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 4 | Derivative | Restricted Stock Units | 2026-03-02 | A | A | 35,300 | $0.00 | 35,300 | D | — · — to — | 35,300 Common Stock | (F2) Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. (F3) The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-03-02 | A | A | 176,550 | $0.00 | 176,550 | D | $30.25 · — to 2036-03-02 | 176,550 Common Stock | (F1) The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026. |